Company / PP&E (Net)
Phathom Pharmaceuticals, Inc. PP&E (Net) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$1.1M
FY2025
5-year range
$650.0K / $2.1M
FY2021-FY2025
Trend
-27.9%
vs FY2024
Sector context
#155 of 193
Health Care
What the data says
Phathom Pharmaceuticals, Inc.'s pp&e (net) of $1M is lower than 80% of companies in the Health Care sector (FY2025). PP&E (Net) has fluctuated over the past 7 years, ranging from $463,000 in FY2019 to $2M in FY2023.
Based on SEC 10-K filings.
$1M in FY2025 with a 5-year CAGR of +1.5%.
Declined from $2M to $1M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -4.1%
- 5-Year CAGR
- +1.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 193This company $1.1M Sector average $777.6M
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +1.5%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 27.9% year-over-year.
- Ranks #155 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -6.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.1M | -27.9% |
| FY2024 | $1.5M | -31.2% |
| FY2023 | $2.1M | +77.8% |
| FY2022 | $1.2M | +85.7% |
| FY2021 | $650.0K | -34.1% |
| FY2020 | $986.0K | +113.0% |
| FY2019 | $463.0K | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026